av Øivind Enger | okt 7, 2020 | News
Sarsia Seed portfolio company Vaccibody AS – was today listed on Oslo Stock Exchange´s Merkur Markets list. ...
av Øivind Enger | okt 1, 2020 | News
It was announced today that Sarsia Seed portfolio company Vaccibody AS enters into $715m lisence and collaboration agreement with Genentech.Low double-digit tiered royalties on sales of commercialized products arising from the partnership are in addition. ...
av Øivind Enger | aug 17, 2020 | News
Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR) announce that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg), Nektar’s CD122-preferential IL-2 pathway agonist, with VB10.NEO,...
av Øivind Enger | mai 28, 2020 | News
Vaccibody announces First Patient Dosed in its VB C-02 trial; a multi-centre, open-label Phase II clinical trial testing a combination of Vaccibody’s VB10.16, a targeted DNA vaccine, and Roche’s PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in...
av Øivind Enger | mai 20, 2020 | News
US biopharmaceutical company Rallybio has announced that they have completed a USD 145 mill Series B financing to advance the company’s portfolio of product candidates targeting devastating rare diseases. Rallybio’s lead candidate is RLYB211 that the...
av Øivind Enger | mai 5, 2020 | News
BerGenBio today announced that the company has raised mNOK via a private placement that took place via an accelerated book building process after close of market on 4 May 2020. Read...
